Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.

Ciaravino V, McCullough T, Cimino G, Sullivan T.

Vox Sang. 2003 Oct;85(3):171-82.

PMID:
14516447
2.

Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective.

Ciaravino V.

Semin Hematol. 2001 Oct;38(4 Suppl 11):12-9. Review.

PMID:
11727281
3.

Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.

Ciaravino V, Hanover J, Lin L, Sullivan T, Corash L.

Transfusion. 2009 May;49(5):985-94. doi: 10.1111/j.1537-2995.2008.02076.x. Epub 2009 Jan 21.

PMID:
19175545
4.

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Klüter H.

Vox Sang. 2004 May;86(4):239-45.

PMID:
15144528
5.

Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.

Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP.

Transfusion. 2008 Apr;48(4):697-705. doi: 10.1111/j.1537-2995.2007.01594.x. Epub 2008 Jan 7.

PMID:
18194378
6.

Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.

Osselaer JC, Debry C, Goffaux M, Pineau J, Calomme G, Dubuc E, Chatelain B, Vandendaele MC, Hsu J, Rheinschmidt M, Lin L.

Transfusion. 2008 Jan;48(1):108-17. Epub 2007 Sep 27.

PMID:
17900283
7.

Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.

Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG; SPRINT Study Group.

Transfusion. 2005 Dec;45(12):1864-75.

PMID:
16371039
8.

Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.

Lin L, Conlan MG, Tessman J, Cimino G, Porter S.

Transfusion. 2005 Oct;45(10):1610-20. Review.

PMID:
16181212
9.

Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.

Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ.

Transfusion. 2005 Sep;45(9):1453-8.

PMID:
16131377
10.

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.

de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L.

Transfusion. 2005 Aug;45(8):1362-72.

PMID:
16078927
11.

Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin.

Hambleton J, Wages D, Radu-Radulescu L, Adams M, MacKenzie M, Shafer S, Lee M, Smyers J, Wiesehahn G, Corash L.

Transfusion. 2002 Oct;42(10):1302-7.

PMID:
12423514
12.

Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.

Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L.

Transfusion. 2006 Jul;46(7):1168-77.

PMID:
16836564
13.

Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.

Ciaravi V, McCullough T, Dayan AD.

Hum Exp Toxicol. 2001 Oct;20(10):533-50. Review.

PMID:
11858518
14.

Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components.

Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K.

Transfusion. 2008 Aug;48(8):1676-84. doi: 10.1111/j.1537-2995.2007.01762.x. Epub 2008 May 22.

PMID:
18503613
15.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
16.

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.

Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG.

Transfusion. 2006 Oct;46(10):1693-704.

PMID:
17002625
17.

Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments.

Cid J, Ramiro L, Martínez N, Palomo M, Magallon O, Claparols M, Ortiz P, Puig L, Pla RP.

Transfus Apher Sci. 2008 Oct;39(2):115-21. doi: 10.1016/j.transci.2008.07.009.

PMID:
18710822
18.

Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.

Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, Porter S, Lin L, Metzel P, Conlan MG; SPRINT Study Group.

Transfusion. 2006 Apr;46(4):562-71.

PMID:
16584432
19.

A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.

Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L.

Transfusion. 2008 Jun;48(6):1061-71. doi: 10.1111/j.1537-2995.2008.01643.x. Epub 2008 Mar 13.

PMID:
18346019
20.

Supplemental Content

Support Center